Compounds > 3,5-dichloro-2-hydroxy-N-(2-methoxy-5-phenylphenyl)benzenesulfonamide
Page last updated: 2024-11-12

3,5-dichloro-2-hydroxy-N-(2-methoxy-5-phenylphenyl)benzenesulfonamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID16747776
CHEMBL ID399379
CHEBI ID95014
SCHEMBL ID16111544

Synonyms (38)

Synonym
CHEMBL399379 ,
3,5-dichloro-2-hydroxy-n-(4-methoxy-biphenyl-3-yl)-benzenesulfonamide
bdbm50209010
BRD-K43620258-001-01-6
bms-303141
CS-2039
HY-16107
SCHEMBL16111544
943962-47-8
bms 303141
c19h15cl2no4s
3,5-dichloro-2-hydroxy-n-(2-methoxy-5-phenylphenyl)benzenesulfonamide
bms303141
3,5-dichloro-2-hydroxy-n-(4-methoxy[1,1'-biphenyl]-3-yl)-benzenesulfonamide
3,5-dichloro-2-hydroxy-n-(4-methoxy-[1,1'-biphenyl]-3-yl)benzenesulfonamide
3,5-dichloro-2-hydroxy-n-(4-methoxybiphenyl-3-yl)benzenesulfonamide
J-690403
AKOS026750433
EX-A119
bms30314
AC-35435
3,5-dichloro-2-hydroxy-n-(2-methoxy-5-phenylphenyl)benzene-1-sulfonamide
CHEBI:95014
NCGC00371135-01
NCGC00371135-08
bms 30314
BCP06495
Q27166773
F17365
gtpl12855
mfcd25976797
FT-0700511
AS-16774
AMY16365
HMS3873N03
HMS3740O11
3,5-dichloro-2-hydroxy-n-(4-methoxy[1,1a?biphenyl]-3-yl)-benzenesulfonamide
A859442

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)		0.51

Dosage Studied

ExcerptRelevanceReference
" Chronic oral dosing of compound 9 in high-fat fed mice lowered plasma cholesterol, triglyceride, and glucose, as well as inhibited weight gain."( 2-hydroxy-N-arylbenzenesulfonamides as ATP-citrate lyase inhibitors.
Biller, S; Chen, B; Chen, L; Cheng, D; Chu, CH; Flynn, N; Harrity, T; Herpin, TF; Jamil, H; Lawrence, RM; Li, JJ; Obermeier, MT; Padmanabha, R; Pike, K; Ponticiello, R; Robl, JA; Sasseville, V; Schnur, D; Tino, JA; Wang, H; Zhao, R, 2007)		0.34
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
biphenylsBenzenoid aromatic compounds containing two phenyl or substituted-phenyl groups which are joined together by a single bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Acetyl-CoA carboxylase 2Homo sapiens (human)IC50 (µMol)12.00000.03400.07870.1940AID307190
AcetylcholinesteraseRattus norvegicus (Norway rat)IC50 (µMol)9.00000.00020.52597.2000AID307190; AID307191
ATP-citrate synthaseHomo sapiens (human)IC50 (µMol)0.31630.13000.27480.4420AID1434016; AID1434770; AID307170
Acetyl-CoA carboxylase 1Homo sapiens (human)IC50 (µMol)6.00000.11601.26466.0000AID307191
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (32)

Processvia Protein(s)Taxonomy
acetyl-CoA metabolic processAcetyl-CoA carboxylase 2Homo sapiens (human)
pentose-phosphate shuntAcetyl-CoA carboxylase 2Homo sapiens (human)
response to nutrientAcetyl-CoA carboxylase 2Homo sapiens (human)
response to xenobiotic stimulusAcetyl-CoA carboxylase 2Homo sapiens (human)
negative regulation of gene expressionAcetyl-CoA carboxylase 2Homo sapiens (human)
positive regulation of lipid storageAcetyl-CoA carboxylase 2Homo sapiens (human)
regulation of glucose metabolic processAcetyl-CoA carboxylase 2Homo sapiens (human)
response to organic cyclic compoundAcetyl-CoA carboxylase 2Homo sapiens (human)
fatty acid oxidationAcetyl-CoA carboxylase 2Homo sapiens (human)
negative regulation of fatty acid beta-oxidationAcetyl-CoA carboxylase 2Homo sapiens (human)
glucose importAcetyl-CoA carboxylase 2Homo sapiens (human)
lactic acid secretionAcetyl-CoA carboxylase 2Homo sapiens (human)
protein homotetramerizationAcetyl-CoA carboxylase 2Homo sapiens (human)
positive regulation of heart growthAcetyl-CoA carboxylase 2Homo sapiens (human)
tricarboxylic acid metabolic processAcetyl-CoA carboxylase 2Homo sapiens (human)
intracellular aspartate homeostasisAcetyl-CoA carboxylase 2Homo sapiens (human)
intracellular glutamate homeostasisAcetyl-CoA carboxylase 2Homo sapiens (human)
energy homeostasisAcetyl-CoA carboxylase 2Homo sapiens (human)
regulation of cardiac muscle hypertrophy in response to stressAcetyl-CoA carboxylase 2Homo sapiens (human)
malonyl-CoA biosynthetic processAcetyl-CoA carboxylase 2Homo sapiens (human)
fatty acid biosynthetic processAcetyl-CoA carboxylase 2Homo sapiens (human)
acetyl-CoA biosynthetic processATP-citrate synthaseHomo sapiens (human)
citrate metabolic processATP-citrate synthaseHomo sapiens (human)
oxaloacetate metabolic processATP-citrate synthaseHomo sapiens (human)
fatty acid biosynthetic processATP-citrate synthaseHomo sapiens (human)
cholesterol biosynthetic processATP-citrate synthaseHomo sapiens (human)
lipid biosynthetic processATP-citrate synthaseHomo sapiens (human)
coenzyme A metabolic processATP-citrate synthaseHomo sapiens (human)
tissue homeostasisAcetyl-CoA carboxylase 1Homo sapiens (human)
acetyl-CoA metabolic processAcetyl-CoA carboxylase 1Homo sapiens (human)
fatty acid biosynthetic processAcetyl-CoA carboxylase 1Homo sapiens (human)
protein metabolic processAcetyl-CoA carboxylase 1Homo sapiens (human)
fatty-acyl-CoA biosynthetic processAcetyl-CoA carboxylase 1Homo sapiens (human)
protein homotetramerizationAcetyl-CoA carboxylase 1Homo sapiens (human)
lipid homeostasisAcetyl-CoA carboxylase 1Homo sapiens (human)
cellular response to prostaglandin E stimulusAcetyl-CoA carboxylase 1Homo sapiens (human)
malonyl-CoA biosynthetic processAcetyl-CoA carboxylase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Processvia Protein(s)Taxonomy
acetyl-CoA carboxylase activityAcetyl-CoA carboxylase 2Homo sapiens (human)
protein bindingAcetyl-CoA carboxylase 2Homo sapiens (human)
ATP bindingAcetyl-CoA carboxylase 2Homo sapiens (human)
biotin bindingAcetyl-CoA carboxylase 2Homo sapiens (human)
identical protein bindingAcetyl-CoA carboxylase 2Homo sapiens (human)
metal ion bindingAcetyl-CoA carboxylase 2Homo sapiens (human)
ATP citrate synthase activityATP-citrate synthaseHomo sapiens (human)
protein bindingATP-citrate synthaseHomo sapiens (human)
ATP bindingATP-citrate synthaseHomo sapiens (human)
metal ion bindingATP-citrate synthaseHomo sapiens (human)
acetyl-CoA carboxylase activityAcetyl-CoA carboxylase 1Homo sapiens (human)
protein bindingAcetyl-CoA carboxylase 1Homo sapiens (human)
ATP bindingAcetyl-CoA carboxylase 1Homo sapiens (human)
identical protein bindingAcetyl-CoA carboxylase 1Homo sapiens (human)
metal ion bindingAcetyl-CoA carboxylase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (13)

Processvia Protein(s)Taxonomy
nucleusAcetyl-CoA carboxylase 2Homo sapiens (human)
mitochondrionAcetyl-CoA carboxylase 2Homo sapiens (human)
mitochondrial outer membraneAcetyl-CoA carboxylase 2Homo sapiens (human)
cytosolAcetyl-CoA carboxylase 2Homo sapiens (human)
mitochondrial fatty acid beta-oxidation multienzyme complexAcetyl-CoA carboxylase 2Homo sapiens (human)
mitochondrionAcetyl-CoA carboxylase 2Homo sapiens (human)
extracellular regionATP-citrate synthaseHomo sapiens (human)
nucleoplasmATP-citrate synthaseHomo sapiens (human)
cytosolATP-citrate synthaseHomo sapiens (human)
membraneATP-citrate synthaseHomo sapiens (human)
azurophil granule lumenATP-citrate synthaseHomo sapiens (human)
extracellular exosomeATP-citrate synthaseHomo sapiens (human)
ficolin-1-rich granule lumenATP-citrate synthaseHomo sapiens (human)
cytosolATP-citrate synthaseHomo sapiens (human)
fibrillar centerAcetyl-CoA carboxylase 1Homo sapiens (human)
cytosolAcetyl-CoA carboxylase 1Homo sapiens (human)
actin cytoskeletonAcetyl-CoA carboxylase 1Homo sapiens (human)
mitochondrionAcetyl-CoA carboxylase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (47)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347172Secondary qRT-PCR qHTS assay for selected Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347167Vero cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347161Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347170Vero cells viability counterscreen for qRT-PCR qHTS assay of selected Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347168HepG2 cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347149Furin counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347153Confirmatory screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347169Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347152Confirmatory screen NINDS AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347157Confirmatory screen GU Rhodamine qHTS for Zika virus inhibitors qHTS2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID307171Inhibition of total lipid synthesis HepG2 cells assessed as incorporation of [14C]total lipids after 6 hrs2007Bioorganic & medicinal chemistry letters, Jun-01, Volume: 17, Issue:11
2-hydroxy-N-arylbenzenesulfonamides as ATP-citrate lyase inhibitors.
AID1434770Inhibition of ATP citrate lyase (unknown origin) using sodium citrate as substrate by ADP-Glo luminescence assay2017Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4
Discovery of furan carboxylate derivatives as novel inhibitors of ATP-citrate lyase via virtual high-throughput screening.
AID307180Reduction of cholesterol level in high-fat diet C57BL/6 mouse at 10 mg/kg2007Bioorganic & medicinal chemistry letters, Jun-01, Volume: 17, Issue:11
2-hydroxy-N-arylbenzenesulfonamides as ATP-citrate lyase inhibitors.
AID307182Reduction of triglycerides in high-fat diet C57BL/6 mouse at 10 mg/kg2007Bioorganic & medicinal chemistry letters, Jun-01, Volume: 17, Issue:11
2-hydroxy-N-arylbenzenesulfonamides as ATP-citrate lyase inhibitors.
AID1434028Inhibition of cancer stemness in snail expressing HMLE cells under 3D culture condition assessed as induction of apoptosis in spheroid at 25 uM by Hoechst 33342/Sytox green staining-based confocal microscopic method2017European journal of medicinal chemistry, Jan-27, Volume: 126Design and synthesis of emodin derivatives as novel inhibitors of ATP-citrate lyase.
AID307187Reduction of body weight gain in high-fat diet C57BL/6 mouse at 100 mg/kg after 29 days2007Bioorganic & medicinal chemistry letters, Jun-01, Volume: 17, Issue:11
2-hydroxy-N-arylbenzenesulfonamides as ATP-citrate lyase inhibitors.
AID307176Tmax in mouse at 10 mg/kg, iv2007Bioorganic & medicinal chemistry letters, Jun-01, Volume: 17, Issue:11
2-hydroxy-N-arylbenzenesulfonamides as ATP-citrate lyase inhibitors.
AID307184Reduction of fasting plasma glucose level in C57BL/6 mouse at 10 mg/kg2007Bioorganic & medicinal chemistry letters, Jun-01, Volume: 17, Issue:11
2-hydroxy-N-arylbenzenesulfonamides as ATP-citrate lyase inhibitors.
AID307191Inhibition of human ACC12007Bioorganic & medicinal chemistry letters, Jun-01, Volume: 17, Issue:11
2-hydroxy-N-arylbenzenesulfonamides as ATP-citrate lyase inhibitors.
AID307185Reduction of fasting plasma glucose level in C57BL/6 mouse at 100 mg/kg2007Bioorganic & medicinal chemistry letters, Jun-01, Volume: 17, Issue:11
2-hydroxy-N-arylbenzenesulfonamides as ATP-citrate lyase inhibitors.
AID307190Inhibition of human ACC22007Bioorganic & medicinal chemistry letters, Jun-01, Volume: 17, Issue:11
2-hydroxy-N-arylbenzenesulfonamides as ATP-citrate lyase inhibitors.
AID1434026Inhibition of cancer stemness in human A549 cells under 3D culture condition assessed as induction of apoptosis in spheroid at 25 uM by Hoechst 33342/Sytox green staining-based confocal microscopic method2017European journal of medicinal chemistry, Jan-27, Volume: 126Design and synthesis of emodin derivatives as novel inhibitors of ATP-citrate lyase.
AID307186Reduction of body weight gain in high-fat diet C57BL/6 mouse at 10 mg/kg after 29 days2007Bioorganic & medicinal chemistry letters, Jun-01, Volume: 17, Issue:11
2-hydroxy-N-arylbenzenesulfonamides as ATP-citrate lyase inhibitors.
AID307172Cytotoxicity against HepG2 cells upto 50 uM by Alamar blue assay2007Bioorganic & medicinal chemistry letters, Jun-01, Volume: 17, Issue:11
2-hydroxy-N-arylbenzenesulfonamides as ATP-citrate lyase inhibitors.
AID307179Increase in food consumption in normal fat diet C57BL/6 mouse at 10 mg/kg2007Bioorganic & medicinal chemistry letters, Jun-01, Volume: 17, Issue:11
2-hydroxy-N-arylbenzenesulfonamides as ATP-citrate lyase inhibitors.
AID307188Reduction of fat in high-fat diet C57BL/6 mouse at 10 mg/kg after 29 days2007Bioorganic & medicinal chemistry letters, Jun-01, Volume: 17, Issue:11
2-hydroxy-N-arylbenzenesulfonamides as ATP-citrate lyase inhibitors.
AID307183Reduction of triglycerides in high-fat diet C57BL/6 mouse at 100 mg/kg2007Bioorganic & medicinal chemistry letters, Jun-01, Volume: 17, Issue:11
2-hydroxy-N-arylbenzenesulfonamides as ATP-citrate lyase inhibitors.
AID1434016Inhibition of ATP citrate lyase (unknown origin) using sodium citrate as substrate after 60 mins by ADP-Glo luminescence assay2017European journal of medicinal chemistry, Jan-27, Volume: 126Design and synthesis of emodin derivatives as novel inhibitors of ATP-citrate lyase.
AID307173Oral bioavailability in mouse at 10 mg/kg2007Bioorganic & medicinal chemistry letters, Jun-01, Volume: 17, Issue:11
2-hydroxy-N-arylbenzenesulfonamides as ATP-citrate lyase inhibitors.
AID307170Inhibition of human recombinant ATP-citrate lyase2007Bioorganic & medicinal chemistry letters, Jun-01, Volume: 17, Issue:11
2-hydroxy-N-arylbenzenesulfonamides as ATP-citrate lyase inhibitors.
AID307181Reduction of cholesterol level in high-fat diet C57BL/6 mouse at 100 mg/kg2007Bioorganic & medicinal chemistry letters, Jun-01, Volume: 17, Issue:11
2-hydroxy-N-arylbenzenesulfonamides as ATP-citrate lyase inhibitors.
AID1434025Inhibition of cancer stemness in human A549 cells under 3D culture condition assessed as reduction in spheroid size at 25 uM by Hoechst 33342/Sytox green staining-based confocal microscopic method2017European journal of medicinal chemistry, Jan-27, Volume: 126Design and synthesis of emodin derivatives as novel inhibitors of ATP-citrate lyase.
AID307178Increase in food consumption in high-fat diet C57BL/6 mouse at 10 mg/kg2007Bioorganic & medicinal chemistry letters, Jun-01, Volume: 17, Issue:11
2-hydroxy-N-arylbenzenesulfonamides as ATP-citrate lyase inhibitors.
AID307174Half life in mouse at 10 mg/kg, iv and po2007Bioorganic & medicinal chemistry letters, Jun-01, Volume: 17, Issue:11
2-hydroxy-N-arylbenzenesulfonamides as ATP-citrate lyase inhibitors.
AID1434027Inhibition of cancer stemness in snail expressing HMLE cells under 3D culture condition assessed as reduction in spheroid size at 25 uM by Hoechst 33342/Sytox green staining-based confocal microscopic method2017European journal of medicinal chemistry, Jan-27, Volume: 126Design and synthesis of emodin derivatives as novel inhibitors of ATP-citrate lyase.
AID307177Total body clearance in mouse at 10 mg/kg, iv and po2007Bioorganic & medicinal chemistry letters, Jun-01, Volume: 17, Issue:11
2-hydroxy-N-arylbenzenesulfonamides as ATP-citrate lyase inhibitors.
AID307189Reduction of fat in high-fat diet C57BL/6 mouse at 100 mg/kg after 29 days2007Bioorganic & medicinal chemistry letters, Jun-01, Volume: 17, Issue:11
2-hydroxy-N-arylbenzenesulfonamides as ATP-citrate lyase inhibitors.
AID307175Cmax in mouse at 10 mg/kg, po2007Bioorganic & medicinal chemistry letters, Jun-01, Volume: 17, Issue:11
2-hydroxy-N-arylbenzenesulfonamides as ATP-citrate lyase inhibitors.
AID1347164384 well plate NINDS Rhodamine confirmatory qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347158ZIKV-mCherry secondary qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347163384 well plate NINDS AMC confirmatory qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347156DAPI mCherry counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (16.67)29.6817
2010's3 (50.00)24.3611
2020's2 (33.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 13.26

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index13.26 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index5.21 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (13.26)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
emodin
Emodin: Purgative anthraquinone found in several plants, especially RHAMNUS PURSHIANA. It was formerly used as a laxative, but is now used mainly as a tool in toxicity studies.. emodin : A trihydroxyanthraquinone that is 9,10-anthraquinone which is substituted by hydroxy groups at positions 1, 3, and 8 and by a methyl group at position 6. It is present in the roots and barks of numerous plants (particularly rhubarb and buckthorn), moulds, and lichens. It is an active ingredient of various Chinese herbs.		2.1510trihydroxyanthraquinoneantineoplastic agent;
laxative;
plant metabolite;
tyrosine kinase inhibitor
emodin anthrone
emodin anthrone: inhibits respiratory-driven solute transport in membrane vesicles of E coli. emodin anthrone : A member of the class of anthracenones that is anthracen-9(10H)-one which carries a methyl group at position 6 and hydroxy groups at positions 1, 3 and 8, respectively. It is an intermediate precursor in the synthesis of hypericin.		2.1510anthracenone;
phenols		fungal metabolite
hydroxycitric acid
[no description available]		2.4820carbonyl compound
ConditionIndicatedRelationship StrengthStudiesTrials
Body Weight
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.		02.0310
Congenital Zika Syndrome
[description not available]		02.2510
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.2510
Zika Virus Infection
A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.		02.2510